SUBSCRIBE
SUBSCRIBE

Cassava Sciences Inc.

NEWS
Lumasiran was granted priority review status by FD
Drug Development
FDA Action Alert: DURECT, Vertex, Alnylam, and Regeneron
Now that July is over, the U.S. Food and Drug Administration (FDA) appears to be back in full swing with a full docket of drug decisions to make. There are four therapeutics with PDUFA dates this week involving six biopharma companies. Here’s a look.
August 3, 2018
 · 
2 min read
 · 
Mark Terry
FDA
FDA Committee Votes 14 to 3 Against Pain Therapeutics’ Remoxy ER
Pain Therapeutics stock plunged 70 percent after a U.S. Food and Drug Administration (FDA) advisory committee voted 14 to 3 against approval of its Remoxy ER for severe pain.
June 27, 2018
 · 
2 min read
 · 
Mark Terry
Policy
For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million
September 27, 2016
 · 
1 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Business
Pain Therapeutics Tanks As Pfizer Walks Away From Remoxy® Deal
October 27, 2014
 · 
2 min read
The Day In Review: Eisai Inc. Buys Morphotek Inc. For $325 Million
March 22, 2007
 · 
1 min read
Drug Development
The Day In Review: Pozen, Inc. Inks Pain Deal With AstraZeneca PLC
August 3, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Pain Therapeutics Gets $150 Million Payment From King Pharmaceuticals®, Inc.
January 3, 2006
 · 
1 min read
Pain Therapeutics, Inc. Late Stage Drugs For Mega-Markets
October 19, 2005
 · 
1 min read
Biotech Developing Abuse-Proof Oxycontin
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Lone Star Bio
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
October 25, 2023
 · 
5 min read
Policy
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
October 12, 2023
 · 
7 min read
Lone Star Bio
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NYCEO to Present on Wednesday, October 11th, at 10:30am ET
October 5, 2023
 · 
1 min read
Drug Development
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
October 2, 2023
 · 
6 min read
Drug Development
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
September 18, 2023
 · 
5 min read
Lone Star Bio
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
September 11, 2023
 · 
8 min read
Lone Star Bio
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences - September 06, 2023
September 6, 2023
 · 
1 min read
Business
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
August 3, 2023
 · 
8 min read
Lone Star Bio
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
July 5, 2023
 · 
12 min read
Lone Star Bio
New Research Shows Simufilam Suppresses Overactive mTOR
June 27, 2023
 · 
5 min read
Load More